News
RNA bundled in lipid nanoparticles trains T cells in mice to eliminate cancer. Coupled with noninvasive imaging, researchers tracked the in situ CAR-T cells to assess their effectiveness and safety.
4d
SurvivorNet on MSNFDA Loosens Safety Requirements For CAR T-Cell Therapies, Paving The Way For Many More Blood Cancer Patients To Access Innovative TreatmentThe FDA has loosened safety restrictions for six CAR T-cell immunotherapies, used in treating a number of blood cancers.
3d
Verywell Mind on MSNCancer's Hidden Toll on Mental Health: What You Need to KnowMedically reviewed by Yolanda Renteria, LPC The beginning of August can signal the final days of summer, college move-in preparations, and squeezing in a final family vacation. But on August 1, 2023, ...
The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...
The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory ...
The FDA issued a complete response letter to Genentech indicating it cannot approve the company’s biologic license ...
Genentech, part of the Roche Group ( OTCQX:RHHBY) ( OTCQX:RHHBF) ( OTCPK:RHHVF ), announced that the U.S. FDA has rejected ...
Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new ...
B-cell lymphoma articles from across Nature Portfolio B-cell lymphoma is a type of blood cancer that affects the B lymphocytes of the immune system. They usually arise in the lymph nodes or in ...
Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.
HealthDay News — For women with breast cancer (BC), BRCA mutations are associated with increased risk of developing breast implant–associated anaplastic large cell lymphoma (BIA-ALCL), according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results